Experimental Drug Shows Promise As a Microbicide

Researchers reported at the Third International AIDS Society Conference on HIV Pathogenesis and Treatment that the experimental HIV nonnucleoside reverse transcriptase inhibitor TMC 120, developed by Tibotec, has shown promise in preventing vaginal transmissions of HIV when applied as a microbicide. Cervical tissue was shown to resist HIV infection up to six days after TMC 120 treatment.